{'fraction_non_alphanumeric': 0.02830188679245283, 'fraction_numerical': 0.009433962264150943, 'mean_word_length': 5.849462365591398, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Adjuvant radiation therapy in pancreatic carcinoma: a reappraisal.

AbstractPancreatic carcinoma is clearly a disease that “gives cancer a bad name.” In general, it is refractory to single modality therapy using surgery radiation therapy, or chemotherapy. While only 10-15% of patients present with resectable disease, approximately 50% of patients with pancreatic carcinoma have only locoregional disease (non-resectable) at diagnosis. For these patients without distant metastases, some recent studies employing combined modality therapy show some promise for improving local control and possibly survival in this devastating disease.